Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period. The primary outcome measures are safety and tolerability of Siponimod in mild AD subjects. The secondary outcome measures are the rates of brain atrophy derived from volumetric MRI (vMRI) as a proxy for neurodegeneration conducted at baseline, 6, 12, and 18 months. The tertiary outcome measures are the changes in cognition and the levels of AD-associated (e.g., Aβ and tau) and inflammatory biomarkers in CSF after Siponimod exposure. In an exploratory effort, we will also measure plasma inflammatory markers during the entire duration of the study to investigate whether one or more of these markers can be used as dynamic surrogate markers of treatment response. Using our unique experience with the repurposing of immunomodulatory drugs for AD (and NCT #04032626), in the present project we are using elements of clinical trial design that we believe were successful and made some adjustments to fit the pharmacologic and toxic properties of Siponimod.

Start Date26 Aug 2025

Sponsor / Collaborator

St. Joseph's Medical Center, Inc.

[+5]

CTR20232992

/ CompletedNot Applicable

西尼莫德片的人体生物等效性研究

[Translation] Study on the bioequivalence of siponimod tablets in healthy volunteers

研究空腹/餐后状态下单次口服受试制剂西尼莫德片与参比制剂西尼莫德片（万立能®）在健康成年受试者体内的药代动力学，评价空腹/餐后状态下口服两种制剂的生物等效性和安全性。

[Translation]

The pharmacokinetics of a single oral dose of the test preparation Siponimod tablets and the reference preparation Siponimod tablets (Vanlin®) in healthy adult subjects were studied in the fasting/postprandial state, and the bioequivalence and safety of the two preparations were evaluated in the fasting/postprandial state.

Start Date23 Sep 2023

Sponsor / Collaborator

Qilu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Siponimod Fumaric Acid

100 Translational Medicine associated with Siponimod Fumaric Acid

100 Patents (Medical) associated with Siponimod Fumaric Acid

333

Literatures (Medical) associated with Siponimod Fumaric Acid

12 Aug 2026·Current Computer-Aided Drug Design

Computational Identification of Potential HMG-CoA Reductase Modulators Through Drug Repurposing: Structural Insights and Therapeutic Implications

Article

Author: Al-Shaheen, Mohammed R⁠. ; Mohammed, Qusay Abdulsattar

Introduction::

HMG-CoA reductase (HMGCR) is a validated lipid-lowering target, but statin intolerance, variable response, and drug-drug interactions justify exploration of mechanistically distinct modulators. This study prioritized approved drugs that may bind predicted non-orthosteric HMGCR pockets.

Methods::

A computational workflow combining homology modeling (SWISS-MODEL; GMQE = 0.95), CB-Dock pocket detection, AutoDock Vina docking, 100 ns all-atom molecular dynamics (MD) simulations (GROMACS 2023.2), MM/PBSA binding-free-energy estimation, and in silico ADMET screening was applied to Fluspirilene, Lenvatinib, Siponimod, and Lumacaftor.

Results::

Two putative non-orthosteric pockets were identified with calculated volumes of 394 Å3 (Pocket 1) and 305 Å3 (Pocket 2). Fluspirilene showed the most favorable Pocket 1 docking score (-9.4 kcal/mol) and MM/PBSA binding-free-energy estimate (-65.2 ± 3.8 kcal/mol), whereas Lumacaftor showed the most favorable Pocket 2 score (-8.9 kcal/mol; MM/PBSA: -55.7 ± 4.1 kcal/mol). MD trajectories supported retention of the selected poses throughout the 100 ns simulation window.

Discussion::

The predicted interactions involved hydrophobic contacts, π-associated interactions, hydrogen bonding, and electrostatic contacts at sites spatially distinct from the canonical statin/HMG-CoA catalytic region. These findings support a non-orthosteric binding hypothesis but do not establish functional allosteric inhibition without enzyme kinetics, direct binding assays, and structural validation.

Conclusion::

The study identifies computationally prioritized candidate scaffolds for putative non-orthosteric HMGCR modulation and defines the biochemical, kinetic, and structural validation required before any therapeutic interpretation.

01 Aug 2026·Therapeutic Advances in Neurological Disorders

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study

Article

Author: Calles Hernández, Carmen ; Agüera Morales, Eduardo ; Díaz Sánchez, María ; Gracia Gil, Julia ; Oreja-Guevara, Celia ; Durán Ferreras, Eduardo ; Cano Orgaz, Antonio Tomás ; Agüado García, Laura ; González Quintanilla, Vicente ; Boyero Durán, Sabas ; Meca-Lallana, Virginia ; Gómez Vicente, Lidia ; Gómez Gutiérrez, Montserrat ; Meca-Lallana, Jose ; Landete Pascual, Lamberto ; Romero Pinel, Lucía ; Blasco Quílez, Rosario ; López Real, Ana ; Otano Martínez, María ; Martín Martínez, Jesus ; Aladro-Benito, Yolanda ; Ares Luque, Adrián ; Lorenzo González, Jose Ramón ; Gascón Giménez, Francisco ; Querol Pascual, María Rosa ; Alonso Torres, Ana María ; Gómez-Estévez, Irene ; Barrero Hernández, Francisco Javier ; Eichau Madueño, Sara ; Caminero Rodríguez, Ana Belén ; Delgado Gil, Virginia

Background::

Siponimod is approved in Europe for active secondary progressive multiple sclerosis (SPMS), but real-world data on its treatment patterns and outcomes in people with SPMS (pwSPMS) is limited.

Objective::

To assess the demographic and clinical characteristics, effectiveness, and safety of siponimod in pwSPMS in a real-world setting.

Design::

Non-interventional/observational, retrospective, multicenter study (28 centers).

Methods::

Patients (⩾18 years) with active SPMS treated with siponimod in routine care were included. Retrospective clinical, radiological, and laboratory data were collected for patients up to 24 months before and 12 months after siponimod treatment.

Results::

In total, 210 participants were included (mean age: 52.5 ± 8.6 years; females: 71.0%). At treatment initiation, the mean Expanded Disability Status Scale (EDSS) score was 5.7 ± 1.2. The mean time since multiple sclerosis diagnosis and the median time since active SPMS diagnosis were 16.7 ± 8.9 years and 1.3 (0.3; 4.4) years, respectively. Common comorbidities included psychiatric disorders and dyslipidemia (20.6%, each). Regarding working status, 55.9% with available information showed incapacity for work. Prior to siponimod, 44.3% received highly effective therapies: fingolimod (20.5%), rituximab (9.5%), ocrelizumab (5.2%), natalizumab (4.8%), and alemtuzumab (2.4%). After 1 year, 82.8% of the patients remained stable in terms of disability progression, 94.3% were free of relapses, and 85.7% did not present radiological disease activity; 46.2% experienced adverse events, 8.6% experienced serious adverse events, and 26 (12.4%) patients discontinued permanently.

Conclusion::

In the study cohort, pwSPMS had high disability scores and comorbidities; more than half were unable to work, and over 40% had previously received high-efficacy therapies. After 1 year of siponimod treatment, most pwSPMS showed no signs of disease activity, with stabilized EDSS scores and relapses and new T2 or gadolinium-T1 lesions, as well as a favorable safety profile.

01 Aug 2026·ANNALS OF PHARMACOTHERAPY

Effect of Sphingosine-1-Phosphate Receptor Modulators on Insulin Resistance: A Review

Review

Author: Caíña López, Sandra ; Rodríguez Regal, Ana ; Martínez Martínez, Luciano ; Bartolomé Figueroa, Andrea

Objective::

The objective is to review the potential impact of sphingosine-1-phosphate (S1P) receptor modulators on insulin resistance in patients with multiple sclerosis, including underlying mechanisms and clinical evidence.

Data sources::

A literature search was conducted in PubMed for publications from inception through November 2025. Additional sources, including therapeutic positioning reports and official product information (Summary of Product Characteristics), were also reviewed.

Study selection and data extraction::

Relevant English and Spanish language articles were extracted and evaluated.

Data synthesis::

Sphingosine-1-phosphate receptors (S1PR) regulate both immunological and metabolic functions, representing a key therapeutic target in multiple sclerosis. Agents such as fingolimod, siponimod, ozanimod and ponesimod bind to these receptors, thereby preventing lymphocyte migration into the central nervous system. Preclinical evidence suggests that S1P signaling participates in insulin receptor and Akt pathways, affecting glycogen synthesis, glucose uptake and β-cell survival. Clinical experience, including a case of a patient with type 1 diabetes and multiple sclerosis treated with ponesimod, indicates potential increases in insulin requirements and hyperglycemia, although formal human studies are lacking.

Relevance to patient care and clinical practice::

Clinicians should monitor glycemic control in patients with multiple sclerosis receiving S1PR modulators, especially those with pre-existing metabolic disorders. Awareness of potential insulin resistance may guide drug selection and metabolic management. Further prospective studies are warranted to clarify clinical implications.

Conclusions::

S1PR modulators are effective disease-modifying therapies in multiple sclerosis, but emerging evidence suggests a possible impact on insulin signaling and glucose metabolism. Vigilance in metabolic monitoring is recommended, particularly in patients with diabetes or other risk factors for insulin resistance.

News (Medical) associated with Siponimod Fumaric Acid

07 Oct 2026

·www.biospace.com

Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026

Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety pro remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and remibrutinib in MS Phase III NEOS late-breaker will expand evidence for Kesimpta ® (ofatumumab) in pediatric MS, where current approved treatment options remain limited New Kesimpta data from STHENOS study in treatment-naive relapsing MS and from KATHAROS breastfeeding study will be presented Basel, October 07 , 2026 – Novartis will present new data from its multiple sclerosis (MS) portfolio with 46 abstracts at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. Among these is a late-breaking abstract featuring the Phase III REMODEL-1/-2 results, underscoring the potential of remibrutinib and reinforcing the company’s long-standing commitment to advancing care for people living with MS. A second late-breaking abstract will present new Kesimpta ® (ofatumumab) data in pediatric MS, where significant treatment needs remain. Additional presentations will further expand the Kesimpta evidence base, including research on pregnancy outcomes and breastfeeding that aims to inform family planning decisions, as well as the use of Kesimpta versus disease-modifying therapies commonly used as first-line treatments in treatment-naïve patients. “For decades, Novartis has helped shape the treatment landscape for people living with multiple sclerosis through scientific innovation,” said Nazem Atassi, Global Head, Neuroscience and Gene Therapy Development, Novartis. “At MSToronto2026, we are sharing Phase III results from REMODEL-1 and REMODEL-2 evaluating remibrutinib, an oral BTK inhibitor, alongside new evidence across our MS portfolio. Together, these data reflect our continued commitment to addressing unmet needs across different stages of life and disease.” Investor call on remibrutinib in MS Following the presentation of the REMODEL data at MSToronto2026, Novartis will host a conference call for investors to provide updates on the data and the potential for remibrutinib in MS. Key abstracts include: Abstract Title Presentation Details Remibrutinib Efficacy and Safety of Remibrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 REMODEL-1/-2 Trials Presentation ID O139 Oral Presentation October 23, 11:25 – 11:35 a.m. ET Kesimpta (ofatumumab) Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Multiple Sclerosis: The Innovative Phase 3 NEOS Study Presentation ID O138 Oral Presentation October 23, 11:15 – 11:25 a.m. ET Ofatumumab Versus Physicians’ Choice of Disease Modifying Therapy in Treatment-Naive People Living With Relapsing Multiple Sclerosis: Final Efficacy Results of The Phase 3b STHENOS Study Presentation ID P0390 Poster Session 1 October 21, 4:30 – 6:30 p.m. ET Ofatumumab Versus Physicians’ Choice of Disease-Modifying Therapy in Treatment-Naive People Living With Relapsing Multiple Sclerosis: Final Safety and Tolerability Results of The Phase 3b STHENOS Study Presentation ID EP2632 ePoster Ofatumumab Versus Physicians’ Choice of Disease Modifying Therapy in Treatment-Naive People Living With Relapsing Multiple Sclerosis: Final Healthcare Resource Utilization Results of the Phase 3b STHENOS Study Presentation ID EP2625 ePoster Evaluating Ofatumumab Excretion in Breastmilk of Women Living With Relapsing Multiple Sclerosis: Interim Results of the Phase 4 KATHAROS Study Presentation ID EP2565 ePoster Pregnancy and Infant Outcomes in Women With Relapsing Multiple Sclerosis Following Exposure to Ofatumumab: Latest Evidence From the PRIM Study Presentation ID P1139 Poster Session 2 October 22, 4:30 – 6:30 p.m. ET About Novartis Neuroscience Neurological diseases are deeply personal, affecting people of any age, from newborns to seniors, often striking in the prime of life. In multiple sclerosis (MS), Novartis has helped shape the treatment landscape for decades through scientific innovation and leadership in advancing care for people living with MS. We remain focused on addressing unmet needs and pursuing new approaches that may improve outcomes for people across the MS journey. Building on this foundation, we're doubling down on our commitment to neurology, expanding our legacy of innovation in MS and spinal muscular atrophy (SMA) to work in neuroimmunology, neurodegeneration, and neuromuscular diseases. Our goal is to protect people’s health across their lifespan, developing more treatment options that lead to better outcomes. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

Phase 3

12 Jun 2026

·www.prnewswire.com

Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced the appointment of Dr. Dhavalkumar Patel as Scientific Advisor. Dr. Patel brings an outstanding track record of therapeutic innovation spanning over two decades in industry and academia. He is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology. Prior to joining Sana Biotechnology in 2024, Dr. Patel served as Executive Vice President and Chief Scientific Officer of UCB, where he and his teams contributed to the registration of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®) and zilucoplan (Zilbrysq®). Prior to UCB, he spent 10 years at Novartis, most recently as the Head of Research of the Novartis Institutes for BioMedical Research (NIBR) Europe. During his tenure, he led research in the autoimmune, transplantation, and inflammation disease areas, contributing to the registration of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®) in multiple indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Dr. Patel served as a member of the Board of Directors of Inflazome prior to its acquisition by Roche in 2020. He currently serves on the Boards of Directors for Priothera, Quell Therapeutics, and RE-AIM Therapeutics, and serves as Chair of the Board of Directors for Mimetas BV. Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. He also spent nine years at the Duke University School of Medicine, culminating in his position as the Chief of the Division of Allergy and Immunology. Dr. Patel received his B.S., M.D., and Ph.D. in Microbiology and Immunology from Duke University, and is board certified in internal medicine, rheumatology, and allergy & immunology. "We are thrilled to welcome Dr. Patel to our Scientific Advisory Board," said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. "His outstanding combination of deep immunological science, proven drug development success, and board-level strategic insight will be a tremendous asset to us. We look forward to his guidance as we continue to build a leading immunology pipeline." "I am honored to join Harbour BioMed as a Scientific Advisor," said Dr. Dhavalkumar Patel. "Harbour BioMed has built a compelling portfolio of novel antibody candidates targeting key immune pathways, and I believe the company is well-positioned to make meaningful progress in areas of high unmet medical need. I look forward to working closely with the team to help advance these programs from discovery through development and ultimately to patients." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUSTM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIxTM AI platform, accelerating the development of innovative therapies. By integrating Harbour Mice®, HBICE®, HCAb PLUSTM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit . SOURCE Harbour BioMed 21% more press release views with Request a Demo

Executive Change

02 Feb 2026

·www.biospace.com

Teva Canada Announces Strategic Partnership with Novartis Canada to Relaunch Mayzent® for Multiple Sclerosis Patients in Canada

TORONTO , Feb. 2, 2026 /CNW/ - Teva Canada Limited (Teva Canada) is announcing a new commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. (Novartis Canada) for Mayzent® (siponimod), an innovative oral treatment for secondary progressive multiple sclerosis (SPMS) with active disease. Under the partnership, Teva Canada will assume exclusive responsibility for the promotion, distribution, and commercialization of Mayzent® in Canada. This collaboration leverages Teva's established central nervous system (CNS) expertise and national commercial infrastructure, ensuring continued access to Mayzent® for Canadian patients and healthcare professionals. The agreement is designed to maximize the reach and impact of Mayzent®, building on Teva's established history with neurologists and MS specialists across the country. "This is about more than a product - it's about people," said Fabien Paquette, General Manager, Teva Canada. "Through this partnership, we are reaffirming our dedication to the MS community and to patient-centred care. Teva Canada is proud to lead with purpose, ensuring access and support for those who need it most. We are all in for better health." "This agreement reflects our shared responsibility to support people living with MS," said Dimitri Gitas, Country President, Novartis Canada "Through this partnership, we're strengthening support for Canadians living with multiple sclerosis and advancing better health outcomes nationwide." Mayzent® is indicated in Canada for the treatment of patients with secondary progressive multiple sclerosis (SPMS) with active disease, as evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability. About Teva Canada Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is proud to celebrate 60 years of serving the health of Canadians. As one of the world's largest suppliers of generic, biosimilar, and innovative medicines, we are all in for better health - committed to delivering reliable, high-quality treatments. With facilities in Markham, Stouffville, Toronto, and Montréal, we employ over 850 people and manufacture 70% of the medicines we sell in Canada locally, reinforcing our commitment to accessibility and supporting the Canadian economy. Learn more at . Forward-Looking Statements This news release contains forward-looking statements regarding the commercialization of Mayzent® in Canada. Actual results may differ materially due to various risks and uncertainties. SOURCE Teva Canada

100 Deals associated with Siponimod Fumaric Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D11072 D11460	Siponimod Fumaric Acid	L04AE03	DB12371

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis, Secondary Progressive	European Union	Novartis Europharm Ltd.	13 Jan 2020
Multiple Sclerosis, Secondary Progressive	Iceland	Novartis Europharm Ltd.	13 Jan 2020
Multiple Sclerosis, Secondary Progressive	Liechtenstein	Novartis Europharm Ltd.	13 Jan 2020
Multiple Sclerosis, Secondary Progressive	Norway	Novartis Europharm Ltd.	13 Jan 2020
Multiple Sclerosis	United States	Novartis Pharmaceuticals Corp.	26 Mar 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple sclerosis relapse	Phase 3	United States	Novartis Pharmaceuticals Corp.	14 Feb 2019
Rhabdomyosarcoma	Phase 3	United States	Novartis Pharmaceuticals Corp.	14 Feb 2019
Alzheimer Disease	Phase 2	United States	Novartis AG	26 Aug 2025
Alzheimer Disease	Phase 2	United States	Laboratory Corporation of America Holdings	26 Aug 2025
Mild cognitive disorder	Phase 2	United States	Novartis AG	26 Aug 2025
Mild cognitive disorder	Phase 2	United States	Laboratory Corporation of America Holdings	26 Aug 2025
Cerebral Hemorrhage	Phase 2	United States	Novartis Pharmaceuticals Corp.	24 Dec 2017
Hemorrhagic stroke	Phase 2	United States	Novartis Pharmaceuticals Corp.	24 Dec 2017
Polymyositis	Phase 2	United States	Novartis Pharmaceuticals Canada, Inc.	24 Apr 2013
Polymyositis	Phase 2	Canada	Novartis Pharmaceuticals Canada, Inc.	24 Apr 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECTRIMS2025	Not Applicable	Multiple Sclerosis, Secondary Progressive	225	Siponimod	npzfqezqaj(jbbwshduua) = Other common adverse effects included infections, elevated liver enzymes, and vertigo. Hypertension occurred less frequently, while isolated cases of macular edema and left bundle branch block were observed. No cases of skin malignancy, seizures, or opportunistic infections were noted. xapmbvpuem (djpejtsste )	Negative	24 Sep 2025
ECTRIMS2025	Not Applicable	Multiple Sclerosis, Secondary Progressive	335	Fampridine alone	hdljsepwgt(wccsrcibij) = wnloklwtzc iazxhpyjgm (hkcbmdiayq )	Positive	24 Sep 2025
ECTRIMS2025	Not Applicable	Multiple Sclerosis, Secondary Progressive	335	Siponimod alone	hdljsepwgt(wccsrcibij) = qpyjminyan iazxhpyjgm (hkcbmdiayq )	Positive	24 Sep 2025
ECTRIMS2025	Not Applicable	Multiple Sclerosis, Secondary Progressive	160	Siponimod	ginmalpnlf(fgsxqsfzmo) = persistent lymphopenia being the most frequently reported adverse event uqpxolcpmt (rofujavuax ) View more	Negative	24 Sep 2025
NCT04926818 (NEOS, ECTRIMS2025)	Phase 3	Multiple Sclerosis	129	Ofatumumab	lyavfyqivl(oizgdmsdsa) = igkopjuhgi yjxfxtuxvx (pvmyicsnvr ) View more	Positive	24 Sep 2025
NCT04925557 (CTgov)	Phase 2/3	Multiple Sclerosis, Secondary Progressive	8	Ocrevus (Ocrevus)	brbgqvjsxs(vfzcujihrp) = hyrvrxpezx yztlstctsa (mjskpstvoi, odoijlofry - nzvgytbxym) View more	-	13 May 2025
NCT04925557 (CTgov)	Phase 2/3	Multiple Sclerosis, Secondary Progressive	8	Mayzent (Mayzent)	brbgqvjsxs(vfzcujihrp) = idxgcgidmj yztlstctsa (mjskpstvoi, zyuxwfgdeo - ftubokkhgf) View more	-	13 May 2025
NCT03623243 (EXCHANGE, Pubmed \| Mult Scler)	Phase 3	Multiple sclerosis relapse	185	Siponimod	xoqcamsooo(iachrfrwzc) = 3.8% (n = 7) xjdlkpmyeh (hyuglwddut ) View more	Positive	01 May 2025
ECTRIMS2024	Not Applicable	Multiple Sclerosis, Secondary Progressive	31	Siponimod	genvesfdut(wuaxkiqnos) = dypiisicvh xoqkqxslor (zbymrndodk ) View more	Negative	18 Sep 2024
ECTRIMS2024	Not Applicable	Multiple Sclerosis, Secondary Progressive	189	Siponimod	vgumadmoek(ntyiaeyeqc) = zkblwjacan uooeuygfxj (laxdkzpmcn ) View more	Positive	18 Sep 2024
RESYZE (ECTRIMS2024)	Not Applicable	Multiple Sclerosis, Secondary Progressive	210	Siponimod	ehzuflmyxg(kzfyrzddxs) = hlatybbvks hucqqwnuui (ygdhdbzkwb ) View more	Positive	18 Sep 2024
ECTRIMS2024	Not Applicable	Multiple sclerosis relapse	113	Siponimod	npkdwnbkfo(zapoyflklt) = rquevfaarh mzrasuojzr (cjrjgjpflo ) View more	Positive	18 Sep 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis